Skin cancer is diagnosed in nearly 1.5 million patients each year (1). While patients with basal and squamous cell carcinomas are provided with 5-year survival rates at nearly 100% and 90%, respectively, patients diagnosed with cutaneous melanoma (metastatic melanoma) are provided 5-year survival rates at 91.4% at stage I and 24.6% at stage IV (2-5). We mined published microarray datasets (6, 7) to determine in an unbiased fashion and at the level of the transcriptome genes most differentially expressed in the primary tumors of patients with the deadliest type of skin cancer, malignant melanoma. We found significant differential expression of the gene encoding NAD kinase, NADK, when comparing melanoma tumor tissue from the human skin to the tissue of origin. NADK mRNA was present at significantly higher quantities in melanoma tissues as compared to normal tissues from the skin. Analysis of human survival data revealed that expression of NADK in melanoma tissues was not correlated with overall survival in patients with malignant melanoma. NADK expression changes may be important for the initiation or progression of malignant melanoma in humans.